--- canonical_name: Hoodia alternate_names: Hoodia gordonii, Hoodia parviflora, P57, Bushman's Hat, Xhoba, Queen of the Namib, Kalahari Cactus canonical_topic: Hoodia for Health & Longevity short_topic_lc: hoodia creation_date: 2026-0825-1658 creator_ai_fullname: Opus 5 ep_keywords: Appetite Suppressants, Steroidal Glycosides, Anti-Obesity Herbs --- # Hoodia for Health & Longevity
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Hoodia gordonii, Hoodia parviflora, P57, Bushman's Hat, Xhoba, Queen of the Namib, Kalahari Cactus ## Motivation Hoodia is a group of spiny, leafless succulent plants from the deserts of southern Africa. The best-known of them, *Hoodia gordonii*, was chewed by San hunters to blunt hunger and thirst on long tracking trips. That practice turned the plant into one of the most heavily marketed natural appetite suppressants of the 2000s. Interest grew after South African government chemists isolated a steroid-like sugar compound from the stems and patented it. A drug company and, later, a large consumer-goods company each licensed the compound, invested heavily, and then walked away. Meanwhile, products labelled Hoodia flooded the market, and repeated laboratory testing found that many contained little or none of the plant. This review sets out what the published evidence shows: how Hoodia is thought to act on hunger signalling, what the human and animal studies actually measured, which side effects were recorded, and how product quality can be judged. It also examines who paid for the key studies and what that means for reading them. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading A short, curated set of high-level sources that cover Hoodia's ethnobotany, chemistry, clinical testing and commercial history in depth. * [*Hoodia gordonii*: to eat, or not to eat](https://pubmed.ncbi.nlm.nih.gov/24955559/) - Smith & Krygsman, 2014 The single most useful risk-benefit appraisal of the plant, arguing that the appetite and weight effects may be downstream of the adverse effects seen at therapeutic doses. * [*Hoodia gordonii*: an up-to-date review of a commercially important anti-obesity plant](https://pubmed.ncbi.nlm.nih.gov/21259185/) - Vermaak et al., 2011 The most complete account of the chemistry, quality-control problems, supply constraints and benefit-sharing controversy, and of how thin the efficacy and safety literature really is. * [Effects of 15-d repeated consumption of *Hoodia gordonii* purified extract on safety, ad libitum energy intake, and body weight in healthy, overweight women: a randomized controlled trial](https://pubmed.ncbi.nlm.nih.gov/21993434/) - Blom et al., 2011 The only published placebo-controlled trial of a purified *Hoodia gordonii* extract in humans, and the source of nearly every clinical safety signal attributed to the plant. * [Indigenous use of *Hoodia gordonii* and appetite suppression](https://pubmed.ncbi.nlm.nih.gov/17681262/) - Lee & Balick, 2007 Expert ethnobotanical commentary on how the San actually used the plant, and why that traditional pattern of use differs sharply from daily supplement dosing. * [Evidence for the efficacy and safety of herbal weight loss preparations](https://pubmed.ncbi.nlm.nih.gov/30738773/) - Farrington et al., 2019 Places Hoodia alongside four other popular slimming herbs, with useful comparative context on herb-drug interaction risk and the weakness of supplement regulation. *Note on priority experts:* none of the six priority expert platforms (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, Lifespan.io) has published a substantive article, episode or lecture on Hoodia. Life Extension Magazine names hoodia only in passing, as one ingredient in a celebrity longevity-regimen interview, and lifeextension.com lists a Hoodia product; neither discusses the plant in any depth. Hoodia's commercial peak preceded most of these platforms, and the topic has since faded from longevity-oriented commentary, so peer-reviewed narrative sources are used instead. ## Grokipedia [Hoodia](https://grokipedia.com/page/Hoodia) Covers the botany, San ethnobotanical use, the commercial arc and the conservation status of the whole genus in one place, with more supply-chain and benefit-sharing detail than most clinical sources. ## Examine [Bushman's Hat](https://examine.com/supplements/bushmans-hat/) Grades the evidence on one trial with 49 participants, notes that P57 does not readily reach the brain, and gives the commonly sold dose alongside the observation that it overlaps the toxic dose in mice. ## ConsumerLab [Hoodia (*Hoodia gordonii*) Supplements Review Article](https://www.consumerlab.com/reviews/hoodia-hoodia-gordonii/hoodia/) Explains why no product testing was performed — no quality standard for Hoodia exists — and pairs the review with recall notices on Hoodia products found to contain no Hoodia at all. ## Systematic Reviews The systematic evidence relevant to Hoodia sits inside broader reviews of slimming supplements rather than in Hoodia-specific syntheses. * [Plant extracts with appetite suppressing properties for body weight control: a systematic review of double blind randomized controlled clinical trials](https://pubmed.ncbi.nlm.nih.gov/23876572/) - Astell et al., 2013 Of 14 double-blind trials across ten plant extracts, the Hoodia trial showed no significant effect on satiety, energy intake or body weight. * [Adverse effects of herbal medicines: an overview of systematic reviews](https://pubmed.ncbi.nlm.nih.gov/23472485/) - Posadzki et al., 2013 An umbrella review of 50 systematic reviews that classifies *Hoodia gordonii* among 15 herbs carrying moderately severe adverse effects. * [A Systematic Review of the European Rapid Alert System for Food and Feed: Tendencies in Illegal Food Supplements for Weight Loss](https://pubmed.ncbi.nlm.nih.gov/33574758/) - Koncz et al., 2020 Hoodia accounted for 66 of 117 unauthorised-plant alerts in European slimming supplements between 1988 and 2019, the largest single share. *Trade-off coverage:* the claimed effect (appetite suppression and weight loss) is represented by Astell et al.; the principal risks (adverse effects and adulteration) by Posadzki et al. and Koncz et al. No systematic review quantifies the forgone benefit of choosing Hoodia over an evidence-supported weight-management approach, and that side is therefore unrepresented in the systematic literature. ## Mechanism of Action Hoodia's activity is attributed to oxypregnane steroidal glycosides — steroid-like molecules carrying sugar chains — of which P57AS3 (shortened to P57) is the most studied. Injected into the brain ventricles of rats, P57 raised adenosine triphosphate (ATP, the cell's main energy currency) in hypothalamic neurons by 50–150% and cut 24-hour food intake by 40–60%, and it did not bind known receptors including the sodium-potassium pump ([MacLean & Luo, 2004](https://pubmed.ncbi.nlm.nih.gov/15312781/)). Competing explanations place the action in the gut. The glycoside H.g.-12 activates the human bitter-taste receptors TAS2R7 and TAS2R14 (sensing proteins that also line the intestine) and triggers release of cholecystokinin, a gut hormone signalling fullness ([Le Nevé et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20930049/)). A third account names gordonoside F, not P57, as the active agent, acting on GPR119 — a receptor on pancreatic and intestinal cells that promotes insulin release and lowers food intake ([Zhang et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25246581/)). Pharmacologically, P57 is stable in human liver preparations, is pumped back out of intestinal cells by the P-glycoprotein and multidrug-resistance transporters, and weakly inhibits the drug-metabolising enzyme CYP3A4 ([Madgula et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18612942/)). In mice, oral availability was 47.5%, peak levels came at 0.6 hours, the elimination half-life was short and similar by mouth and by vein, and tissues cleared within four hours; distribution ran kidney above liver above brain, and after oral dosing P57 was undetectable in brain ([Madgula et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20414860/)). ## Historical Context & Evolution Hoodia was food and water, not medicine. San and Khoi communities of the Kalahari ate the peeled stems of several *Hoodia* species to hold off hunger and thirst on hunts and during scarcity — an intermittent, whole-plant use recorded in ethnobotanical reports as far back as 1796 ([Lee & Balick, 2007](https://pubmed.ncbi.nlm.nih.gov/17681262/)). The shift to health optimisation began in 1963, when South Africa's Council for Scientific and Industrial Research screened indigenous food plants and found appetite suppression. Structural work in the 1980s and 1990s isolated P57, and the Council patented it in 1995, licensed it to Phytopharm, and sublicensed development to Pfizer, which returned the rights in 2003. Unilever took the programme on in 2004, cultivated more than 70 hectares, built a food-grade extraction process, and abandoned the project in 2008 ([Knight et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22410259/)). The original findings deserve to be read directly. The Council's own animal work showed dose-dependent falls in food intake and body mass in rats at 6.25–50 mg/kg, and outperformed fenfluramine on body weight in a comparison arm ([van Heerden et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17603088/)). Those results were never retracted; what changed is that the single human trial, published in 2011, did not reproduce them, and that the plant was placed under trade restriction in 2005 while the retail market filled with mislabelled product. Whether that reflects an inactive plant, a wrong extract, a wrong dose, or a wrong duration remains open. ## Expected Benefits An important framing point for readers already optimising diet, training and sleep: the outcome that matters here is not population weight change but whether Hoodia adds anything to an appetite-management strategy that a motivated person is already executing. On that question the evidence is thin, and much of it was generated by parties with a direct commercial stake in the answer — the Council for Scientific and Industrial Research and its licensees Phytopharm and Unilever on one side, and an Israeli *Hoodia parviflora* producer on the other. Both funding directions are flagged where they arise. ### High 🟩 🟩 🟩 No benefit of Hoodia reaches this evidence level. No meta-analysis, and no replicated set of randomised controlled trials (studies where participants are randomly assigned to treatment or placebo), supports any outcome. ### Medium 🟩 🟩 No benefit reaches this level either. The three randomised human trials disagree with each other, use different species and preparations, and each had a commercial sponsor. ### Low 🟩 #### Appetite Suppression & Short-Term Weight Reduction ⚠️ Conflicted Evidence is conflicted. Purified *Hoodia gordonii* extract changed neither intake nor weight over 15 days in 49 women ([Blom et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21993434/)). Two smaller *Hoodia parviflora* trials reported reduced body measurements ([Landor et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25453380/); [Perna et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32218424/)). Species, dose and sponsor differ. **Magnitude:** Purified *Hoodia gordonii* extract at 2 × 1110 mg/day for 15 days changed neither energy intake nor body weight; whole *Hoodia parviflora* at 9 mg/day for four weeks gave −1.6 kg body weight (95% confidence interval, the range the true effect most likely occupies, −2.5 to −0.7 kg) and −2.1 cm waist circumference. No pooled estimate exists, because no meta-analysis has combined the trials. ### Speculative 🟨 #### Glucose-Stimulated Insulin Secretion Gordonoside F activates GPR119 and enhanced insulin release and lowered food intake in mice; the effect vanished in GPR119 knockout animals. Basis is mechanistic and preclinical only ([Zhang et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25246581/)). #### Reduced Insulin Resistance & Liver Fat Oral *Hoodia parviflora* extract improved glucose tolerance, liver enzymes and liver fat in two rodent models of fatty liver. Basis is animal work only ([Mizrahi et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31634046/)). #### Mood Elevation via Monoamine Signalling Extract reduced immobility in the mouse forced-swim test and raised brain serotonin, noradrenaline and dopamine. No controlled human data exist; the basis is rodent behavioural work alone ([Citó et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25493384/)). #### Antioxidant & Antiviral Activity Ethanol and ethyl acetate extracts inhibited two viral enzymes and scavenged free radicals in test tubes. The work is entirely laboratory-based, at concentrations with no demonstrated relationship to oral dosing ([Kapewangolo et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27776523/)). ## Benefit-Modifying Factors * **Bitter-taste receptor variants:** One proposed pathway runs through the bitter receptors TAS2R7 and TAS2R14. Common variants in this receptor family alter bitter sensitivity, so responders and non-responders to a gut-mediated satiety signal are biologically plausible, though untested for Hoodia. * **Drug-transporter genetics:** P57 is a substrate for the P-glycoprotein and multidrug-resistance efflux pumps. Variants in the ABCB1 gene that encodes P-glycoprotein change intestinal efflux, and so plausibly change how much reaches the circulation from a fixed dose. * **Baseline body fat and energy balance:** Rodent work found weight loss in both lean and obese animals, but the human trial recruited only overweight women. Effects in already lean, energy-balanced individuals are unmeasured, and appetite suppression offers less headroom there. * **Sex:** Every participant in the only placebo-controlled *Hoodia gordonii* trial was female. Whether men respond similarly to appetite endpoints is unknown, and no trial has been powered to compare the sexes. * **Pre-existing metabolic disease:** The GPR119 pathway implicates insulin secretion, so people with impaired glucose tolerance or fatty liver are the group where a metabolic benefit would be most visible. A trial in fatty liver was completed but never reported results. * **Age:** Appetite suppression is a liability rather than a benefit in older adults at the upper end of this audience, where declining intake, sarcopenia (age-related muscle loss) and unintentional weight loss already threaten function. Expected benefit narrows sharply with age. ## Potential Risks & Side Effects For a risk-aware reader, the dominant hazard is not the plant's own pharmacology but what is actually inside the bottle. ### High 🟥 🟥 🟥 #### Adulterated, Substituted or Undeclared-Drug Products Hoodia's supply has never matched its demand, and the resulting substitution is the best-documented hazard associated with the name. Chemical fingerprinting, DNA barcoding and regulatory alerts converge on the same picture: many retail products contain another *Hoodia* species, an unrelated succulent, or no Hoodia at all, and slimming supplements as a category are frequently spiked with prohibited pharmaceuticals such as sibutramine and 2,4-dinitrophenol ([Koncz et al., 2020](https://pubmed.ncbi.nlm.nih.gov/33574758/); [Gathier et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23865560/)). **Magnitude:** Hoodia generated 66 of 117 unauthorised-plant alerts (56.4%) in European weight-loss supplements between 1988 and 2019, peaking at 30 alerts in 2017; across the same slimming-supplement dataset 202 of 319 flagged products (63.3%) contained an unapproved synthetic drug. ### Medium 🟥 🟥 #### Blood Pressure and Heart Rate Elevation ⚠️ Conflicted The clearest clinical safety signal. In the only placebo-controlled *Hoodia gordonii* trial, blood pressure, pulse and heart rate all rose significantly relative to placebo, alongside electrocardiogram changes ([Blom et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21993434/)). A mechanistic study found beta-adrenergic activity (action on the receptors that speed the heart) in a commercial Hoodia product, consistent with a sympathomimetic effect — mimicking the body's fight-or-flight signalling ([Roza et al., 2013](https://pubmed.ncbi.nlm.nih.gov/24307991/)). The *Hoodia parviflora* consumer trial reported no cardiovascular events, so the finding is not universal across preparations. **Magnitude:** Directionally upward at 2 × 1110 mg/day of purified extract over 15 days in overweight women, with the effect emerging on repeated rather than single dosing; the literature reports no outcome figure for these endpoints beyond statistical significance, because the single controlled trial gives none and no second trial exists. #### Nausea and Vomiting Gastrointestinal intolerance was the reason the extract was judged less well tolerated than placebo, with episodes of nausea and vomiting driving the tolerability gap ([Blom et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21993434/)). Drug-reference sources classify these as moderately severe ([Drugs.com natural-products monograph](https://www.drugs.com/npp/hoodia.html)). Mechanistically this fits bitter-receptor activation and cholecystokinin release, which would make the nausea inseparable from the proposed satiety pathway rather than an incidental effect. **Magnitude:** Directionally more frequent than placebo at 2 × 1110 mg/day over 15 days, resolving on discontinuation; the trial report gives no incidence figure for the individual symptom, and no second trial exists to pool with. #### Altered Skin Sensation Disturbances of skin sensation — tingling, numbness or crawling sensations — were the third component of the tolerability signal in the controlled trial and are unusual enough to be worth flagging ([Blom et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21993434/)). They are consistent with the fight-or-flight activity described above. Onset was during dosing and the reports did not persist as chronic events. **Magnitude:** Directionally more frequent than placebo at 2 × 1110 mg/day over 15 days; no outcome figure is reported for this symptom, which has been measured in a single trial of 49 women. #### Liver-Related Laboratory Abnormalities Total bilirubin and alkaline phosphatase (an enzyme raised when bile flow or bone turnover is disturbed) rose significantly on extract relative to placebo, with blood urea nitrogen (a nitrogen waste product) falling ([Blom et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21993434/)). These were biochemical changes in healthy women over 15 days, not clinical liver disease, but they are the reason drug-reference sources advise caution in anyone with compromised liver function ([Drugs.com natural-products monograph](https://www.drugs.com/npp/hoodia.html)). **Magnitude:** Directionally upward for bilirubin and alkaline phosphatase at 2 × 1110 mg/day over 15 days; no outcome figure is available beyond statistical significance because this trial is the only source of controlled human biochemistry. ### Low 🟥 #### Liver Injury from Multi-Ingredient or Adulterated Products Herbals and dietary supplements account for a rising share of liver injury in the United States Drug-Induced Liver Injury Network, a prospective multicentre registry ([Navarro et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25043597/)). Hoodia appears there among the few single-ingredient products implicated, though most exposure runs through adulterated or multi-ingredient slimming products. **Magnitude:** 130 of 839 registry cases (15.5%) were attributed to herbals and supplements over 2004–2013; of 175 implicated products with identifiable ingredients, 32 (18%) were single-ingredient products. Death or transplantation followed in 13% of non-bodybuilding supplement cases versus 3% for conventional medicines. #### Loss of Lean Muscle Mass The most longevity-relevant finding in the animal literature. In lean and obese rats given extract for 14 days, the weight lost came from reduced skeletal muscle fibre size and reduced fat cell size ([Smith & Krygsman, 2014](https://pubmed.ncbi.nlm.nih.gov/25066203/)). Any intake-lowering agent carries this risk; here it was measured at tissue level. **Magnitude:** Directionally downward for both adipose cell size and muscle fibre size at 80 or 160 mg/kg twice daily over 14 days in rats, at doses producing significant weight loss; no human body-composition study has been performed, so no human figure exists. ### Speculative 🟨 #### Cardiac Hypertrophy The same rodent programme reported ventricular hypertrophy — thickening of the heart wall — alongside the weight loss. Basis is a single animal study at doses far above human intake, with no human imaging data. #### Impaired Fetal Development Mouse and rabbit studies found reduced fetal weight and delayed bone formation, but only at doses that markedly suppressed maternal feeding. Basis is animal reproductive toxicology; no human pregnancy exposure data exist. #### Blunted Thirst Signalling The San used Hoodia to suppress thirst as well as hunger. If that carries over, dehydration could be masked during heat or hard training. Basis is ethnobotanical report and mechanism, with no controlled measurement. ## Risk-Modifying Factors * **Drug-transporter genetics:** Variants in ABCB1, the gene encoding the P-glycoprotein efflux pump that removes P57 from intestinal cells, plausibly raise systemic exposure in poor-efflux carriers and with it the dose-linked cardiovascular and gastrointestinal effects. * **Baseline liver and bile markers:** Anyone starting with bilirubin or alkaline phosphatase near the top of range, or with fatty liver, has less biochemical headroom before the rises seen in the controlled trial become clinically meaningful. * **Sex:** All controlled *Hoodia gordonii* safety data come from women, so the cardiovascular and biochemical signals are characterised in one sex only. Men have no dedicated safety dataset for this preparation. * **Pre-existing cardiovascular disease:** Fight-or-flight activity makes uncontrolled hypertension, arrhythmia (irregular heart rhythm), structural heart disease and a long corrected QT interval — a measure of the heart's electrical recovery time — the conditions where the observed changes matter most. * **Age:** Older adults at the upper end of this audience carry more arrhythmia risk, more medicines cleared by CYP3A4, and more sarcopenia, so the same exposure produces a worse risk profile than in a 35-year-old. ## Key Interactions & Contraindications * **CYP3A4 substrates (simvastatin, midazolam, tacrolimus, apixaban):** Caution. P57 weakly inhibits CYP3A4 in laboratory assays, which could raise levels of narrow-margin substrates. Separate dosing is not protective; the described mitigation is monitoring for substrate-specific effects such as muscle damage or bleeding. * **P-glycoprotein substrates (digoxin, dabigatran, rivaroxaban, colchicine):** Caution. P57 is transported by P-glycoprotein and competition could raise substrate exposure, risking digoxin toxicity or bleeding. Where a substrate level can be measured, a two-week recheck is the usual safeguard. * **Antihypertensives and rate-control agents (amlodipine, lisinopril, bisoprolol):** Caution. Hoodia's pressure-raising and rate-raising effect opposes the drug, risking loss of blood-pressure or rate control. Home monitoring twice weekly detects this before a clinic visit would. * **Stimulants and sympathomimetics (pseudoephedrine, high-dose caffeine, ephedra, yohimbine, phenylephrine):** Absolute contraindication in combination. Additive adrenergic load risks hypertensive surges, palpitations and arrhythmia. The only mitigation is not combining them. * **Monoamine oxidase inhibitors (an older antidepressant class: phenelzine, tranylcypromine, selegiline):** Absolute contraindication. Rodent data show raised noradrenaline, serotonin and dopamine; combination risks a dangerous blood-pressure surge and serotonin excess. No dose adjustment helps. * **Over-the-counter agents (decongestant cold remedies, caffeine tablets, weight-loss patches, laxative teas):** Caution. These are the commonest unlogged source of additive stimulant load and of undeclared sibutramine. Label-checking and separation from other slimming products are the described mitigations. * **Supplements with additive stimulant or heat-producing effects (bitter orange, green tea extract, guarana, *Acacia rigidula*, forskolin):** Caution. Stacking these compounds compounds the pressure-raising effect. Single-agent use with four weeks between changes is the mitigation described in the literature. * **Supplements with additive hepatic burden (green tea extract, kava, *Garcinia cambogia*, high-dose niacin):** Caution. Overlapping liver-injury signals make attribution impossible and the combined risk unquantified. Avoiding the stack, and liver-enzyme testing where one is already in use, are the stated mitigations. * **Other interventions:** Caution when combined with GLP-1 receptor agonists (medicines such as semaglutide that slow stomach emptying), aggressive caloric restriction or prolonged fasting. Additive nausea and additive lean-mass loss are the predictable consequences, and concurrent use has no described safeguard. **Populations who should avoid Hoodia:** * Pregnant or breastfeeding women — animal data show delayed fetal bone formation at maternally toxic doses, and no human data exist. * Anyone with uncontrolled hypertension (blood pressure ≥ 140/90 mmHg on treatment). * Anyone with a corrected QT interval above 440 milliseconds, a history of atrial or ventricular arrhythmia, or a family history of premature sudden cardiac death. * Anyone with a heart rate below 50 or above 100 beats per minute at rest, or with left ventricular hypertrophy. * Anyone with active or recent liver disease, or liver enzymes above twice the upper limit of normal. * Anyone with a history of an eating disorder, or with a body mass index below 20 kg/m². * Adults over 70, and anyone with diagnosed sarcopenia or unintentional weight loss. * Anyone taking a monoamine oxidase inhibitor, or a narrow-margin CYP3A4 or P-glycoprotein substrate that cannot be monitored. ## Risk Mitigation Strategies * **Species-verified material only:** A certificate of analysis naming the species and the analytical method — chromatographic fingerprint or DNA identification — is the single defence against the adulteration and undeclared-drug risk that dominates this intervention. * **Pre-start cardiac screening:** A resting electrocardiogram and two weeks of home blood-pressure readings detect the prolonged corrected QT interval, arrhythmia or hypertension that turn the observed pressure-raising effect into a genuine hazard. * **Quarter-dose start with titration over four weeks:** Protocols of this shape open at roughly 250 mg of extract once daily and double no more often than every two weeks, so nausea, palpitations and skin sensations surface before full exposure. * **Total exposure capped at 15–30 days:** No controlled human data exist beyond 40 days. A fixed stop date prevents open-ended exposure to the liver-enzyme and blood-pressure changes seen in the only placebo-controlled trial. * **Defined stop triggers:** The cardiovascular and liver-injury warning signs are resting heart rate above 100 beats per minute, systolic pressure more than 10 mmHg above baseline, palpitations, jaundice, dark urine, and right upper abdominal pain. * **Lean-mass protection throughout:** Protein at 1.6–2.2 g/kg body weight daily with two to three resistance sessions weekly directly counters the skeletal muscle fibre loss observed in rodents given Hoodia extract. * **Whole-stack stimulant audit:** A pre-start inventory of every supplement, cold remedy and caffeine source, with overlapping adrenergic agents removed, addresses the additive fight-or-flight load behind the most serious plausible adverse events. ## Therapeutic Protocol * **No established practitioner protocol:** Neither an effective nor a safe dose has been established, and no clinic or professional body publishes a Hoodia protocol. What follows is reconstructed from trial regimens and product labels, not from clinical practice. * **Trial-derived regimen:** The Unilever-run trial used 1110 mg of purified *Hoodia gordonii* extract twice daily, one hour before breakfast and dinner, for 15 days. This produced adverse effects without measurable appetite or weight benefit. * **Retail-label regimen:** Commercial products are typically labelled at about 1 g of an extract standardised to 70% or more steroidal glycosides, twice daily, roughly an hour before meals. No evidence supports this dose as active. * **Whole-plant alternative:** A competing approach uses whole dried or frozen *Hoodia parviflora* aerial parts rather than a purified *Hoodia gordonii* extract — 3 g of frozen cube daily in the consumer trial, popularised by Israeli cultivators in the Arava. * **European regulatory ceiling:** The European Food Safety Authority judged dried *Hoodia parviflora* aerial parts safe only up to 9.4 mg daily ([Turck et al., 2017](https://pubmed.ncbi.nlm.nih.gov/32625297/)) — two orders of magnitude below retail extract labelling. The two approaches are irreconcilable. * **Best time of day:** Both regimens dose about one hour before the two largest meals. Late-evening dosing is best avoided given the stimulant profile and its potential effect on sleep onset. * **Half-life and dose splitting:** Rodent pharmacokinetics show peak levels near 0.6 hours and tissue clearance within four hours, with a short elimination half-life. That short exposure window is why every regimen splits the dose rather than giving it once daily. * **Genetic considerations:** No gene-based dose testing is validated for Hoodia. ABCB1 variants affecting the P-glycoprotein efflux pump and CYP3A4 activity are the theoretically relevant ones, because both govern P57 exposure and interaction potential. * **Sex-based differences:** Dosing guidance comes almost entirely from women — the *Hoodia gordonii* trial enrolled women only, and the *Hoodia parviflora* trials included few men. No male dose-finding data exist and no basis exists for scaling by body weight. * **Age-related considerations:** Appetite suppression in adults over 65 risks accelerating sarcopenia and unintentional weight loss. Where used at all in this group, the lower end of any range and the shortest duration apply. * **Baseline biomarkers:** Baseline blood pressure, resting heart rate, liver enzymes, bilirubin and body composition determine whether a protocol should start at all, and provide the comparators for the stop rules. * **Pre-existing conditions:** Fatty liver, impaired glucose tolerance and treated hypertension are the conditions most likely to alter response — the first two because of the GPR119 insulin pathway, the third because of the opposing pressure-raising effect. ## Discontinuation & Cycling * **Not a lifelong intervention:** No safety data exist beyond 40 days of continuous use. Hoodia is at most a short, bounded intervention, and nothing in the evidence supports indefinite daily consumption. * **Withdrawal effects:** None are documented. The controlled trial reported no rebound in energy intake or body weight after stopping, which is unsurprising given that neither changed during dosing. * **Tapering:** No taper is required. The short elimination half-life and absence of receptor-level dependence mean abrupt cessation carries no described physiological penalty; abrupt stopping is in fact the correct response to any stop-rule trigger. * **Cycling:** No cycling schedule has been tested for efficacy or tolerance. If used at all, a 15–30 day block followed by a minimum four-week washout with repeat liver and cardiovascular checks is the conservative structure. * **Post-cessation monitoring:** Blood pressure, resting heart rate, liver enzymes and bilirubin are rechecked four weeks after stopping, to confirm any on-treatment biochemical drift has returned to baseline. ## Sourcing and Quality * **Species identity is the first question:** *Hoodia gordonii* and *Hoodia parviflora* have different regulatory status, different clinical data and different dose ranges. A label saying only "Hoodia" is not adequate; the species name is the minimum disclosure. * **Certificate-backed authentication:** A chromatographic fingerprint or a DNA-based identity test is what distinguishes verified material. Both DNA barcoding and validated real-time genetic detection now exist for the genus and are used by enforcement laboratories. * **Stated glycoside content:** Reputable extracts declare percentage steroidal glycosides or P57 content. Absence of any marker specification means the product cannot be compared to any dose used in research. * **Third-party testing is essential, not optional:** No compendial quality standard for Hoodia exists, which is why ConsumerLab has never rated products. Independent identity and contaminant testing by a laboratory accredited to ISO 17025 is the practical substitute. * **Trade-permit provenance:** All *Hoodia* species are listed under Appendix II of the international endangered-species trade convention. Legitimate suppliers hold cultivation and export permits; material without them is likely wild-harvested or substituted. * **Cultivated over wild-collected:** Commercial plantations in South Africa and Israel provide traceable, batch-consistent material. Wild collection drove both the conservation listing and the substitution problem that followed. ## Practical Considerations * **Time to effect:** Subjective appetite change, where reported, appeared within the first ten days; the body-measurement change in the whole-plant trial took 40 days. The controlled extract trial saw nothing at 15 days. * **Common pitfall — trusting the label:** The most frequent mistake is assuming the capsule contains Hoodia. Regulatory alerts and court settlements repeatedly involve products with no detectable Hoodia, sometimes with undeclared pharmaceuticals instead. * **Common pitfall — dose escalation to force an effect:** Because bioavailability is low, users often raise the dose. The dose producing effect in mice overlaps the toxic dose, so escalation moves toward harm rather than benefit. * **Common pitfall — ignoring lean mass:** Treating any appetite suppressant as a standalone tool without protein and resistance training invites the muscle-fibre loss documented in rodents given Hoodia. * **Regulatory status:** In the United States Hoodia is an unapproved dietary supplement, never evaluated for safety or efficacy. In the European Union *Hoodia gordonii* is an unauthorised novel food, and only *Hoodia parviflora* has a safety opinion ([Turck et al., 2017](https://pubmed.ncbi.nlm.nih.gov/32625297/)). * **Cost and payer incentives:** Extract capsules are cheap; authenticated, permit-backed material is not. Because Hoodia costs a fraction of prescription weight-management drugs, insurers and national health systems carry a structural incentive to favour low-cost unproven options — a bias worth noting when reading guideline framing. ## Interaction with Foundational Habits * **Sleep:** Direct and potentially disruptive. Sympathomimetic beta-adrenergic activity, plus the pulse and blood-pressure elevation recorded in the controlled trial, argue against dosing within six hours of bedtime. No sleep architecture study exists for Hoodia, so the concern is mechanistic. Confining doses to before breakfast and before an early dinner is the practical control. * **Nutrition:** Direct and potentiating in the wrong direction. Suppressed intake without deliberate protein targeting accelerates lean-mass loss. Protein at 1.6–2.2 g/kg daily, prioritised at both meals flanking a dose, is the described counter, and pairing Hoodia with prolonged fasting or very-low-calorie phases compounds the appetite and nausea effects. * **Exercise:** Indirect and potentially blunting. Reduced energy intake undermines training quality and recovery, and rodent data show muscle fibre shrinkage, so hypertrophy work is the session type most at risk. Two to three resistance sessions weekly are the described counter, and the possible blunting of thirst argues against dosing before hard or hot-weather training. * **Stress management:** Direct and stimulating. The adrenergic profile and the rodent monoamine findings suggest Hoodia adds to rather than reduces sympathetic tone, which is the opposite of what most stress protocols aim for. For anyone already using stimulants for alertness, Hoodia forms part of that load rather than sitting separate from it. ## Monitoring Protocol & Defining Success Before starting, the baseline comprises two weeks of twice-weekly home blood-pressure and resting heart-rate readings, a resting electrocardiogram, a liver panel covering alanine aminotransferase (an enzyme released when liver cells are damaged), alkaline phosphatase and total bilirubin, blood urea nitrogen, fasting glucose and glycated haemoglobin, and a body-composition measurement separating fat mass from fat-free mass. Ongoing monitoring runs home blood pressure and resting heart rate every second day, with the liver panel and blood urea nitrogen repeated at day 15, the electrocardiogram repeated at day 15 if any cardiovascular symptom appears, and body composition and the full panel repeated four weeks after stopping. Beyond 30 days, the full panel runs monthly. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Blood pressure | 105–120 / 65–78 mmHg, and no rise above 10 mmHg systolic from personal baseline | The endpoint that rose significantly on Hoodia extract | Seated, after five minutes rest, same time each day; conventional cut-off of 140/90 mmHg is far too permissive as a stop rule here | | Resting heart rate | 50–70 beats per minute, and no rise above 8 beats from personal baseline | Second component of the sympathomimetic signal | Measured on waking before caffeine; wearable overnight averages are more sensitive than a single reading | | Corrected QT interval | Below 430 milliseconds | Screens for the conduction risk that makes stimulant load dangerous | Requires an electrocardiogram; above 440 milliseconds is an exclusion criterion, not merely a caution | | Alanine aminotransferase | 10–26 U/L (women), 10–30 U/L (men) | Detects liver-cell injury, the registry-level concern | An enzyme released when liver cells are damaged; conventional labs flag only above 40–55 U/L, which misses meaningful drift | | Alkaline phosphatase | 45–90 U/L | Rose significantly on extract in the controlled trial | An enzyme raised when bile flow or bone turnover is disturbed; paired with gamma-glutamyl transferase (a bile-duct enzyme absent from bone) to separate liver from bone origin | | Total bilirubin | 0.3–0.9 mg/dL | Second liver marker that rose in the same trial | A yellow pigment from red-cell breakdown; the inherited, harmless Gilbert's syndrome raises it and is excluded before a rise is attributed to Hoodia | | Blood urea nitrogen | 12–18 mg/dL | Fell significantly on extract; also tracks protein intake | A nitrogen waste product; a fall alongside suppressed appetite is a useful early flag of under-eating protein | | Fasting glucose | 75–90 mg/dL | Tests the proposed insulin-secretion pathway | Fasted 10–12 hours; paired with fasting insulin to compute insulin resistance if a metabolic effect is the goal | | Glycated haemoglobin | 4.8–5.3% | Confirms whether any glucose change persists | A three-month average of blood sugar; too slow for a 15–30 day protocol, so useful only for before-and-after framing | | Fat-free mass | No established target; track change from the individual's own baseline, aiming for no loss | The lean-mass loss seen in rodents is the main longevity-relevant harm | Same method each time — dual-energy X-ray absorptiometry preferred over bioimpedance; measured fasted and hydrated | Qualitative markers worth tracking alongside the numbers: * Hunger and craving intensity, scored once daily at a fixed time on a simple 0–10 scale. * Nausea, vomiting or early fullness, recorded as present or absent after each dose. * Skin sensations — tingling, numbness or crawling — which were a distinct signal in the controlled trial. * Palpitations, restlessness or a sense of heightened arousal, especially in the evening. * Sleep onset latency and subjective sleep quality. * Training quality: session energy, load maintained, and recovery between sessions. * Any jaundice, dark urine, pale stool or right upper abdominal discomfort — immediate stop signals. Success is a measurable fall in hunger and craving scores with no rise in blood pressure or resting heart rate, no drift in liver markers, and no loss of fat-free mass. ## Emerging Research * **No active clinical trials:** A search of the trial registry returns three Hoodia studies, all completed and none with posted results: [NCT01306422](https://clinicaltrials.gov/study/NCT01306422), [NCT00816465](https://clinicaltrials.gov/study/NCT00816465) and [NCT00693264](https://clinicaltrials.gov/study/NCT00693264). No new trial has been registered since 2011. * **The unreported fatty-liver trial:** [NCT00816465](https://clinicaltrials.gov/study/NCT00816465) randomised 20 patients with biopsy-proven fatty liver disease to Hoodia or placebo, quadruple-blinded, with insulin resistance and safety as primary endpoints over 30–60 days. It completed in 2010; publishing it would materially change the metabolic picture either way. * **The unreported cardiac safety trial:** [NCT00693264](https://clinicaltrials.gov/study/NCT00693264) was a randomised crossover in 15 healthy volunteers measuring PR and RR intervals (electrocardiogram timings for electrical conduction and heart rate), blood pressure and cardiac output over eight hours after a single 750 mg capsule. Its unpublished results are the most direct test of the cardiovascular signal. * **GPR119 as a target:** [Zhang et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25246581/) identified gordonoside F rather than P57 as a GPR119 agonist, raising both insulin secretion and satiety in mice. Work confirming this would strengthen the case and redirect it toward a different molecule and a metabolic endpoint. * **A regulated species alternative:** The European Food Safety Authority's 2017 opinion on dried *Hoodia parviflora* set a supplement ceiling of 9.4 mg per day from a rodent safety threshold ([Turck et al., 2017](https://pubmed.ncbi.nlm.nih.gov/32625297/)). Further toxicology could widen or close that narrow authorised window. * **Authentication technology:** A validated real-time genetic assay for the genus is now available to enforcement laboratories ([Fraiture et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41685176/)). Wider deployment could weaken the commercial case by quantifying how much retail product contains no Hoodia. * **Biosynthesis of the glycosides:** Characterisation of the plant's oxidosqualene cyclases (enzymes that build its steroid backbone) ([Parveen et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38256784/)) opens a route to fermentation-produced glycosides, which would remove the supply and adulteration constraints that have shaped this field. * **What would settle it:** An independent, adequately powered trial of at least 12 weeks, in both sexes, using authenticated material with declared glycoside content, measuring energy intake, body composition, blood pressure and liver markers. Nothing of that design has been attempted. ## Conclusion Hoodia is a desert plant whose stems were eaten by San hunters to hold off hunger and thirst. A steroid-like compound from those stems suppressed feeding in rats, was patented, and was licensed to two large companies in turn — both of which spent heavily and then stopped. The claimed benefit is appetite suppression and weight loss, and the evidence for it is genuinely conflicted. One placebo-controlled trial of a purified extract found nothing; two smaller trials of the whole plant of a different species found something. All were paid for by companies selling or developing the product, and that applies equally to the study most often cited as showing the plant fails and to those cited as showing it works. Neither side of this record is independent. Against that sits a clearer set of harms. The controlled trial recorded higher blood pressure, faster pulse, nausea, vomiting, odd skin sensations and shifts in liver-related blood markers. Animal work showed the weight lost came partly from muscle. And the most reliably documented hazard is not the plant at all but the market around it: a large share of products carrying the name have been found to contain another plant, no Hoodia, or an undeclared drug. For someone already managing diet, training and sleep deliberately, the honest reading is that the evidence base is too small and too compromised to know what Hoodia does, while the quality and cardiovascular concerns are concrete. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**